NEW YORK, July 9 - Sequenom has agreed to exclusively license HiberGen's SNaPIT genotyping technology for use with its MassArray mass spectrometry platform, the companies said Monday.
The license will allow San Diego-based Sequenom to develop and commercialize reagents and software for the MassArray system using HiberGen's technology. In return, Sequenom will pay HiberGen a license fee and royalties from sales of any SNaPIT-related products that Sequenom develops.
HiberGen, a population genomics and genotyping business based in Dublin, Ireland, will continue to use its SNaPIT technology to identify genetic markers associated with disease. The company also hopes to find other partners to license the SNaPIT technology for additional applications.
"Sequenom's reputation as a leader in SNP analysis, together with its strong links with academic and research centers make them an ideal partner for HiberGen as we pursue our strategy of out-licensing SNaPIT for use on a variety of detection platforms," Maurice Treacy, Chief Executive of HiberGen, said in a statement.